Newsfeeds - Spark Newswire

1 minute read

Uncategorized

Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study

Today, 3:09 PM

Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion’s lead candidate, FPI-1434, in…

FUSN

4 minute read

Uncategorized

9 Health Care Stocks Showing Unusual Options Activity In Today’s Session

By Benzinga Insights

Today, 3:09 PM

This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.

ABBV

1 minute read

Uncategorized

Merck Announces Organon, Standalone Company, Is Positioned To Deliver Low To Mid-single Digit Revenue Growth Off 2021 Base

By Benzinga Newsdesk

Today, 3:09 PM

Standalone company positioned to deliver low to mid-single digit revenue growth off 2021 base Future growth opportunities include Women's Health and Biosimilars businesses; Established Brands portfolio expected to

MRK

8 minute read

Uncategorized

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge

By Shanthi Rexaline

Today, 3:09 PM

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.

ABUS

1 minute read

Uncategorized

Why Is Merck’s Stock Trading Lower Today?

By Tyree Gorges

Today, 3:09 PM

Merck & Co (NYSE: MRK) shares are trading lower after the company reported worse-than-expected EPS and sales results.

MRK

4 minute read

Uncategorized

Novel Approach to Cancer From Lixte Biotechnology Could Be a General way to Enhance a Variety of Standard Treatments

By Silvia Munoz Campo

Today, 3:09 PM

The following article is sponsored by Lixte Biotechnology Holdings, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

JAZZ